Baidu
map

Nature Commun:人体皮肤细胞可转变成胰岛β细胞

2016-01-07 MedSci MedSci原创

新的细胞在动物模型中防止糖尿病发病。加利福尼亚大学Gladstone研究所科学家已成功将人体皮肤细胞转化为功能齐全的胰腺细胞。新的细胞可以感受葡萄糖水平的变化,产生胰岛素,并且在移植到小鼠体内后保护小鼠免受糖尿病。

新的细胞在动物模型中防止糖尿病发病。

加利福尼亚大学Gladstone研究所科学家已成功将人体皮肤细胞转化为功能齐全的胰腺细胞。新的细胞可以感受葡萄糖水平的变化,产生胰岛素,并且在移植到小鼠体内后保护小鼠免受糖尿病

这项研究发表于Nature Communications,也是细胞重新编程技术的一大进步,这将使科学家能够有效地扩展胰腺细胞的生产,制造数万亿的目标细胞,因此是一个显著的进步。这一成就为疾病建模和药物筛选打开了大门,为糖尿病患者带来了个性化的细胞治疗。

UCSF糖尿病中心Matthias Hebrok博士认为这项研究结果第一次证明成人皮肤细胞可以用来有效地快速生成具有功能的胰腺细胞。 这一发现开辟了患者特异性胰岛β细胞特性分析和优化细胞治疗方法的机会。

在这项研究中,科学家首先用药物将皮肤细胞转化为内胚层祖细胞,内胚层祖细胞是发育早期的细胞,具有可以转变成多个不同类型的器官的分子和遗传特征。用这种方法,细胞不需要经历多能干细胞状态,这意味着科学家可以更快地转化为胰腺细胞。研究人员已经使用了类似的方法创建心脏、脑、肝细胞。

添加了四种分子后,内胚层祖细胞分裂迅速,达到了一百万倍的增殖规模。严格的检测没有发现这些细胞存在任何肿瘤形成的证据,没有细胞异质性,只分化到早期器官特异性细胞程度。

然后科学家们分两步处理这些内胚层细胞,首先分化成胰腺前体细胞,然后变成全功能的胰岛β细胞。最重要的是,这些细胞在动物模型中保护小鼠免受糖尿病的发展,响应葡萄糖水平的变化,能够产生胰岛素。

专家评论

第一作者Gladstone心血管疾病研究所博士后研究员Saiyong Zhu博士认为这项研究第一次说明使用细胞直接重编程方法成功的产生胰岛β细胞。 最后一步是最独特的,也是最难的,是可以重新编程的细胞在培养皿中转化为功能性胰岛细胞的最后一步。

Roddenberry干细胞中心Sheng博士认为这种新的细胞重新编程和扩展模式比以前的方法具有更好的可持续性和可扩展性。使用这种方法可以大规模增加细胞生产,同时在多个步骤保持质量控制。这一发展确保在新的细胞制造过程中更大的调节空间。现在我们可以产生几乎无限数量的与特定患者相匹配的胰岛β细胞。

研究简要介绍

背景:胰岛β细胞是生物医学研究和再生医学的一大兴趣热点。

目的:展示人类成纤维细胞向内皮细胞分化转换过程。

方法:采用非一体化游离的重编程因子结合特异性生长因子和化学化合物。最初的细胞株转化为明确的内胚层祖细胞(CDE细胞),被指定为后前肠样祖细胞(CPF细胞)。CPF细胞和衍生细胞,胰腺内胚层祖细胞(CPE细胞),可以大规模增殖。筛选化合物,体外促进CPE细胞向功能性胰岛β样细胞(CPB细胞)分化成熟。

结果:移植cPB细胞到小鼠体内,cPB细胞表现出葡萄糖刺激的胰岛素分泌,也表现出了体内对化学诱导的糖尿病小鼠的保护作用。

结论:成纤维细胞可转化为人胰岛β细胞。研究有助于未来进一步开放产生大规模功能性β细胞,可能有助于糖尿病患者恢复正常。

原始出处:


2.Saiyong Zhu, Holger A Russ, Xiaojing Wang, et all.Human pancreatic beta-like cells converted from fibroblasts. Nature Communications. Published online 06 January 2016.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (43)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086841, encodeId=848a208684139, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 27 19:29:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749585, encodeId=f2f91e49585c3, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Jan 15 11:29:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694165, encodeId=f4f41694165c2, content=<a href='/topic/show?id=1a688385505' target=_blank style='color:#2F92EE;'>#胰岛β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83855, encryptionId=1a688385505, topicName=胰岛β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9aba29580281, createdName=一闲, createdTime=Thu Oct 06 12:29:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880905, encodeId=d45c188090584, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 27 15:29:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69651, encodeId=5cdc6965150, content=这个好,希望能尽早用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 14:56:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63718, encodeId=d2f763e1859, content=这么说糖尿病患者有希望了希望尽快研究清楚在临床上使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160613/IMG575D9886B86721544.jpg, createdBy=07961686486, createdName=1de4921fm57(暂无匿称), createdTime=Mon Feb 08 15:55:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60356, encodeId=6a1c60356fb, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60355, encodeId=669d60355b9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59655, encodeId=f4e2596557e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59656, encodeId=64fe59656df, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-11-27 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086841, encodeId=848a208684139, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 27 19:29:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749585, encodeId=f2f91e49585c3, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Jan 15 11:29:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694165, encodeId=f4f41694165c2, content=<a href='/topic/show?id=1a688385505' target=_blank style='color:#2F92EE;'>#胰岛β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83855, encryptionId=1a688385505, topicName=胰岛β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9aba29580281, createdName=一闲, createdTime=Thu Oct 06 12:29:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880905, encodeId=d45c188090584, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 27 15:29:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69651, encodeId=5cdc6965150, content=这个好,希望能尽早用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 14:56:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63718, encodeId=d2f763e1859, content=这么说糖尿病患者有希望了希望尽快研究清楚在临床上使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160613/IMG575D9886B86721544.jpg, createdBy=07961686486, createdName=1de4921fm57(暂无匿称), createdTime=Mon Feb 08 15:55:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60356, encodeId=6a1c60356fb, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60355, encodeId=669d60355b9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59655, encodeId=f4e2596557e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59656, encodeId=64fe59656df, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-15 baoya
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086841, encodeId=848a208684139, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 27 19:29:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749585, encodeId=f2f91e49585c3, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Jan 15 11:29:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694165, encodeId=f4f41694165c2, content=<a href='/topic/show?id=1a688385505' target=_blank style='color:#2F92EE;'>#胰岛β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83855, encryptionId=1a688385505, topicName=胰岛β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9aba29580281, createdName=一闲, createdTime=Thu Oct 06 12:29:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880905, encodeId=d45c188090584, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 27 15:29:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69651, encodeId=5cdc6965150, content=这个好,希望能尽早用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 14:56:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63718, encodeId=d2f763e1859, content=这么说糖尿病患者有希望了希望尽快研究清楚在临床上使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160613/IMG575D9886B86721544.jpg, createdBy=07961686486, createdName=1de4921fm57(暂无匿称), createdTime=Mon Feb 08 15:55:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60356, encodeId=6a1c60356fb, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60355, encodeId=669d60355b9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59655, encodeId=f4e2596557e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59656, encodeId=64fe59656df, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086841, encodeId=848a208684139, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 27 19:29:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749585, encodeId=f2f91e49585c3, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Jan 15 11:29:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694165, encodeId=f4f41694165c2, content=<a href='/topic/show?id=1a688385505' target=_blank style='color:#2F92EE;'>#胰岛β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83855, encryptionId=1a688385505, topicName=胰岛β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9aba29580281, createdName=一闲, createdTime=Thu Oct 06 12:29:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880905, encodeId=d45c188090584, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 27 15:29:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69651, encodeId=5cdc6965150, content=这个好,希望能尽早用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 14:56:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63718, encodeId=d2f763e1859, content=这么说糖尿病患者有希望了希望尽快研究清楚在临床上使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160613/IMG575D9886B86721544.jpg, createdBy=07961686486, createdName=1de4921fm57(暂无匿称), createdTime=Mon Feb 08 15:55:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60356, encodeId=6a1c60356fb, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60355, encodeId=669d60355b9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59655, encodeId=f4e2596557e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59656, encodeId=64fe59656df, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-05-27 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=2086841, encodeId=848a208684139, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 27 19:29:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749585, encodeId=f2f91e49585c3, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Jan 15 11:29:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694165, encodeId=f4f41694165c2, content=<a href='/topic/show?id=1a688385505' target=_blank style='color:#2F92EE;'>#胰岛β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83855, encryptionId=1a688385505, topicName=胰岛β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9aba29580281, createdName=一闲, createdTime=Thu Oct 06 12:29:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880905, encodeId=d45c188090584, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 27 15:29:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69651, encodeId=5cdc6965150, content=这个好,希望能尽早用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 14:56:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63718, encodeId=d2f763e1859, content=这么说糖尿病患者有希望了希望尽快研究清楚在临床上使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160613/IMG575D9886B86721544.jpg, createdBy=07961686486, createdName=1de4921fm57(暂无匿称), createdTime=Mon Feb 08 15:55:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60356, encodeId=6a1c60356fb, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60355, encodeId=669d60355b9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59655, encodeId=f4e2596557e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59656, encodeId=64fe59656df, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-03-16 任然

    这个好,希望能尽早用于临床

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2086841, encodeId=848a208684139, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 27 19:29:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749585, encodeId=f2f91e49585c3, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Jan 15 11:29:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694165, encodeId=f4f41694165c2, content=<a href='/topic/show?id=1a688385505' target=_blank style='color:#2F92EE;'>#胰岛β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83855, encryptionId=1a688385505, topicName=胰岛β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9aba29580281, createdName=一闲, createdTime=Thu Oct 06 12:29:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880905, encodeId=d45c188090584, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 27 15:29:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69651, encodeId=5cdc6965150, content=这个好,希望能尽早用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 14:56:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63718, encodeId=d2f763e1859, content=这么说糖尿病患者有希望了希望尽快研究清楚在临床上使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160613/IMG575D9886B86721544.jpg, createdBy=07961686486, createdName=1de4921fm57(暂无匿称), createdTime=Mon Feb 08 15:55:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60356, encodeId=6a1c60356fb, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60355, encodeId=669d60355b9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59655, encodeId=f4e2596557e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59656, encodeId=64fe59656df, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-02-08 1de4921fm57(暂无匿称)

    这么说糖尿病患者有希望了希望尽快研究清楚在临床上使用

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2086841, encodeId=848a208684139, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 27 19:29:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749585, encodeId=f2f91e49585c3, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Jan 15 11:29:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694165, encodeId=f4f41694165c2, content=<a href='/topic/show?id=1a688385505' target=_blank style='color:#2F92EE;'>#胰岛β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83855, encryptionId=1a688385505, topicName=胰岛β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9aba29580281, createdName=一闲, createdTime=Thu Oct 06 12:29:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880905, encodeId=d45c188090584, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 27 15:29:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69651, encodeId=5cdc6965150, content=这个好,希望能尽早用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 14:56:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63718, encodeId=d2f763e1859, content=这么说糖尿病患者有希望了希望尽快研究清楚在临床上使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160613/IMG575D9886B86721544.jpg, createdBy=07961686486, createdName=1de4921fm57(暂无匿称), createdTime=Mon Feb 08 15:55:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60356, encodeId=6a1c60356fb, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60355, encodeId=669d60355b9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59655, encodeId=f4e2596557e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59656, encodeId=64fe59656df, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-27 I come

    有深度

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2086841, encodeId=848a208684139, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 27 19:29:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749585, encodeId=f2f91e49585c3, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Jan 15 11:29:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694165, encodeId=f4f41694165c2, content=<a href='/topic/show?id=1a688385505' target=_blank style='color:#2F92EE;'>#胰岛β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83855, encryptionId=1a688385505, topicName=胰岛β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9aba29580281, createdName=一闲, createdTime=Thu Oct 06 12:29:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880905, encodeId=d45c188090584, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 27 15:29:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69651, encodeId=5cdc6965150, content=这个好,希望能尽早用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 14:56:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63718, encodeId=d2f763e1859, content=这么说糖尿病患者有希望了希望尽快研究清楚在临床上使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160613/IMG575D9886B86721544.jpg, createdBy=07961686486, createdName=1de4921fm57(暂无匿称), createdTime=Mon Feb 08 15:55:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60356, encodeId=6a1c60356fb, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60355, encodeId=669d60355b9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59655, encodeId=f4e2596557e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59656, encodeId=64fe59656df, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-27 I come

    有意思

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2086841, encodeId=848a208684139, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 27 19:29:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749585, encodeId=f2f91e49585c3, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Jan 15 11:29:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694165, encodeId=f4f41694165c2, content=<a href='/topic/show?id=1a688385505' target=_blank style='color:#2F92EE;'>#胰岛β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83855, encryptionId=1a688385505, topicName=胰岛β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9aba29580281, createdName=一闲, createdTime=Thu Oct 06 12:29:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880905, encodeId=d45c188090584, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 27 15:29:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69651, encodeId=5cdc6965150, content=这个好,希望能尽早用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 14:56:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63718, encodeId=d2f763e1859, content=这么说糖尿病患者有希望了希望尽快研究清楚在临床上使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160613/IMG575D9886B86721544.jpg, createdBy=07961686486, createdName=1de4921fm57(暂无匿称), createdTime=Mon Feb 08 15:55:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60356, encodeId=6a1c60356fb, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60355, encodeId=669d60355b9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59655, encodeId=f4e2596557e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59656, encodeId=64fe59656df, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-26 doctording1

    这篇文章有一定深度

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2086841, encodeId=848a208684139, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 27 19:29:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749585, encodeId=f2f91e49585c3, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Jan 15 11:29:00 CST 2016, time=2016-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694165, encodeId=f4f41694165c2, content=<a href='/topic/show?id=1a688385505' target=_blank style='color:#2F92EE;'>#胰岛β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83855, encryptionId=1a688385505, topicName=胰岛β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9aba29580281, createdName=一闲, createdTime=Thu Oct 06 12:29:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880905, encodeId=d45c188090584, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 27 15:29:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69651, encodeId=5cdc6965150, content=这个好,希望能尽早用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 14:56:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63718, encodeId=d2f763e1859, content=这么说糖尿病患者有希望了希望尽快研究清楚在临床上使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160613/IMG575D9886B86721544.jpg, createdBy=07961686486, createdName=1de4921fm57(暂无匿称), createdTime=Mon Feb 08 15:55:00 CST 2016, time=2016-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60356, encodeId=6a1c60356fb, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:56:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60355, encodeId=669d60355b9, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Wed Jan 27 07:55:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59655, encodeId=f4e2596557e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59656, encodeId=64fe59656df, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:37:00 CST 2016, time=2016-01-26, status=1, ipAttribution=)]
    2016-01-26 doctording1

    是一篇不错的文章

    0

相关资讯

Diabetes Obes Metab:依帕列净可降低2型糖尿病患者血压

研究者对2型糖尿病患者进行了一项研究,探究依帕列净对该类患者血压和动脉硬化和血管阻力相关标志物的影响。研究者对两个关于2型糖尿病患者的队列研究进行了数据分析,队列1共有 823名患者服用依帕列净12周,实行24小时血压监测;队列2共有2477名患者服用依帕列净24周,坐在办公室测量血压。研究数据显示,与对照组相比依帕列净使两组队列的收缩压和舒张压均下降(p < 0.001 ),且不增快心率。

Diabetes Obes Metab:非胰岛素降糖药——肠促胰岛素,是否增加胰腺癌风险?

肠促胰岛素属于非胰岛素降糖药物(NIAD),是治疗2型糖尿病(T2DM)的新药物。虽然已有研究证明肠促胰岛素的有效性,但该药物与胰腺癌具有一定联系。目前关于肠促胰岛素和胰腺癌间关系的数据很少,因此研究者进行了一项研究调查两者间联系。该项基于人群的回顾性队列研究使用了CPRD 2007-2012年的数据,纳入182,428名使用NIAD治疗的18岁以上患者,并匹配一名非糖尿病患者为对照组。使用多因素

PLoS One:佛罗里达州18岁以上成人糖尿病前期和糖尿病发生和预测因子

背景:糖尿病前期和糖尿病的患者形成大血管并发症的风险增加,包括心脏病和卒中;这是导致全球死亡的主要原因。本研究的目的是评估糖尿病前期和糖尿病的患病率,并探讨佛罗里达州18年以上成人中的预测因子。方法:数据从佛罗里达州的行为危险因素监测系统(BRFSS)获得,时间为2013年1月至12月。调查研究由Stata 13.1中SVYSEY设计。描述性分析,评估糖尿病前期和糖尿病患者的发生率。应用多元回归模

PLoS One:2型糖尿病增加卒中风险,且男女预后不同

背景:2型糖尿病(T2DM)是缺血性卒中发生迅速增加的危险因素。研究者旨在比较2003和2012间在西班牙糖尿病患者和非糖尿病患者缺血性卒中发生的趋势。方法:研究者选择了国家出院数据中,所有缺血性卒中的住院患者。研究者将糖尿病进行分层,评估了每年事件发生率。研究者扥系诊断和治疗程序的英语,患者共发病及住院预后的趋势。研究者统计了住院死亡率(IHM),住院时间(LOSH)以及出院1个月的在入院率。应

Diabetes Obes Metab:不同胰岛素治疗的2型糖尿病患者急性心梗风险比较

研究者对2型糖尿病患者进行了一项研究,根据胰岛素使用种类将其分组,比较不同组患者的急性心肌梗死(AMI)风险。该研究就2004-2009年间德国保险数据,对2型糖尿病患者进行了一项回顾性队列研究。共涉及了21 501名新的胰岛素使用者。研究数据显示,使用预混胰岛素治疗的患者年龄大于胰岛素类似物或NPH胰岛素治疗患者(平均年龄 70.7 vs. 64.1和61.6岁),且预混胰岛素使用者并存病更多。

糖尿病的患病人数在逐年增加,看看其它国家的严峻形势吧

英国糖尿病协会估计,在英国约有405万人患有糖尿病。其中约有350万名患者为成年人,近20万人患病时间超过1年,患病人数比10年前增加了65%。预计有59万人患有2型糖尿病但尚未正式记录在内。且英国糖尿病患者数目逐渐增加,因此,他们呼吁国家正式糖尿病这一严峻问题,并正式开展糖尿病护理和健康宣教。 Chris Askew指出,近2/3的英国人是超重或肥胖,因此患2型糖尿病的风险增加。他呼吁民众摄入健

Baidu
map
Baidu
map
Baidu
map